APTO

Aptose Biosciences Inc. (APTO) | Rumor.io

Aptose Biosciences

APTO

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about APTO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 3

Aptose Biosciences Inc. (APTO) is described as an "appchain utility driver" with a price of $8.91.
APTO's protocol fee model is seen as a key factor in its pricing power.
The company's stock is mentioned as one of several tokens to diversify in a portfolio to manage beta exposure and correlation risk.

Generated by AI

Sentiment

Of the messages about APTO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	66.67% -16.3
Bearish	—	—	—	33.33% +16.3

Bullish· Feb 26

$APTO has broken through the resistance wall at $0.8890, with a massive 217.78M USD volume spike confirming the move.
The stock's price has surged to $0.9832, up 14.88%, following the announcement of a dividend increase, indicating a bullish sentiment.
The company's strong partnerships and product launches are expected to drive the stock's price higher, with a next target of $1.1856.

Bearish· Feb 12

$APTO is experiencing high short interest, which may be causing it to drop whenever it rises above $0.24.
The company's dilution strategy, including warrant issuance, is a major concern for investors, as it may lead to a decrease in stock value.
$APTO's short-term volatility and frequent price drops make it a high-risk investment, with some investors even questioning its potential to reach $1.

Generated by AI

Topics

Of the messages about APTO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	4.35%
Macro	—	—	—	0%
Earnings	—	—	—	0%
Controversies	—	—	—	0%
Announcements	—	—	—	95.65%
Analysts	—	—	—	0%

Earnings· May 10

Aptose Biosciences Inc. ($APTO) is hosting a Q1 earnings call today at 5:00 PM Eastern.
The call will be streamed live and available on replay.
Investors can tune in to the call for updates on the company's financial performance.

Announcements· Feb 20

Aptose Biosciences Inc. ($APTO) announced positive clinical safety review committee (CSRC) approval to dose escalate in Phase 1/2 Tuscany trial of frontline triple drug therapy with Tuspetinib.
The trial achieved complete responses and favorable safety in the first cohort, indicating potential for the treatment of various diseases.
The CSRC approval allows Aptose to proceed with the next stage of the trial, which may lead to further development and potential commercialization of the treatment.

Technical Analysis· Dec 20

* $APTO is breaking above $0.4400, which could lead to a price increase to $0.45 or $0.50.
* The 100ema level at $0.40/$0.42 is key support for continuation, and if claimed, $APTO could rally big.
* A parabolic breakout is imminent, with a potential price target of $1.43, and a breakout above $0.40 could lead to a massive rally.

Generated by AI

Community

Of the messages about APTO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	62.73%
Newcomers	—	—	—	37.27%

Regulars· Feb 12

Aptose Biosciences' frontline triple drug therapy with tuspetinib achieved notable responses in newly diagnosed AML patients in the Phase 1/2 TUSCANY trial, with two out of three evaluable patients achieving complete remission in Cycle 1.
The drug is active, with 2 CR's in cycle-1 with the TUS+VEN+AZA triplet, indicating a promising approach to treating AML.
APTO has broken through resistance levels, with a new high of the day and a bullish descending wedge forming, suggesting a potential upward trend.

Newcomers· Feb 12

The newcomer is excited about Aptose's Frontline Triple Drug Therapy with Tuspetinib, which achieved notable responses in newly diagnosed acute myeloid leukemia patients in the TUSCANY trial.
The price of Aptose Biosciences has increased by 47% pre-market, causing some investors to take notice and speculate about the stock's potential.
Despite past disappointments, the newcomer is holding onto Aptose Biosciences, hoping that the story will turn around and the company's triple therapy will deliver substantial benefits to patients.

Generated by AI

Also Discussed

Investors talking about APTO also mention

#	Name	Attention
1	CWBR - CohBar, Inc.	——
2	Aurinia Pharmaceuticals IncAUPH	0.01%+0.01
3	BLPH - Bellerophon Therapeutics, Inc.	——
4	AFMD - Affimed N.V.	——
5	MRNS - Marinus Pharmaceuticals, Inc.	——
6	Cellectar Biosciences, Inc.CLRB	0%new
7	SCYNEXIS, Inc. Common StockSCYX	0%-0.02
8	Oncolytics Biotech Inc.ONCY	0%0
9	Simplify Piper Sandler US Small-Cap PLUS Income ETFLITL	0%new
10	Axsome Therapeutics IncAXSM	0.01%0